These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 38880360)
1. KCNE4-dependent modulation of Kv1.3 pharmacology. Sastre D; Colomer-Molera M; de Benito-Bueno A; Valenzuela C; Fernández-Ballester G; Felipe A Biochem Pharmacol; 2024 Aug; 226():116368. PubMed ID: 38880360 [TBL] [Abstract][Full Text] [Related]
2. Functional Consequences of the Variable Stoichiometry of the Kv1.3-KCNE4 Complex. Solé L; Sastre D; Colomer-Molera M; Vallejo-Gracia A; Roig SR; Pérez-Verdaguer M; Lillo P; Tamkun MM; Felipe A Cells; 2020 May; 9(5):. PubMed ID: 32370164 [TBL] [Abstract][Full Text] [Related]
3. The calmodulin-binding tetraleucine motif of KCNE4 is responsible for association with Kv1.3. Solé L; Roig SR; Sastre D; Vallejo-Gracia A; Serrano-Albarrás A; Ferrer-Montiel A; Fernández-Ballester G; Tamkun MM; Felipe A FASEB J; 2019 Jul; 33(7):8263-8279. PubMed ID: 30969795 [TBL] [Abstract][Full Text] [Related]
4. KCNE4 suppresses Kv1.3 currents by modulating trafficking, surface expression and channel gating. Solé L; Roura-Ferrer M; Pérez-Verdaguer M; Oliveras A; Calvo M; Fernández-Fernández JM; Felipe A J Cell Sci; 2009 Oct; 122(Pt 20):3738-48. PubMed ID: 19773357 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues. Straub SV; Perez SM; Tan B; Coughlan KA; Trebino CE; Cosgrove P; Buxton JM; Kreeger JM; Jackson VM Am J Physiol Endocrinol Metab; 2011 Aug; 301(2):E380-90. PubMed ID: 21586699 [TBL] [Abstract][Full Text] [Related]
13. Potassium secretion by voltage-gated potassium channel Kv1.3 in the rat kidney. Carrisoza-Gaytán R; Salvador C; Satlin LM; Liu W; Zavilowitz B; Bobadilla NA; Trujillo J; Escobar LI Am J Physiol Renal Physiol; 2010 Jul; 299(1):F255-64. PubMed ID: 20427469 [TBL] [Abstract][Full Text] [Related]
14. Regulation of human cardiac potassium channels by full-length KCNE3 and KCNE4. Abbott GW Sci Rep; 2016 Dec; 6():38412. PubMed ID: 27922120 [TBL] [Abstract][Full Text] [Related]
15. The Kv1.3 K Varga Z; Tajti G; Panyi G Biol Futur; 2021 Mar; 72(1):75-83. PubMed ID: 34554500 [TBL] [Abstract][Full Text] [Related]
16. Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels. Bartok A; Toth A; Somodi S; Szanto TG; Hajdu P; Panyi G; Varga Z Toxicon; 2014 Sep; 87():6-16. PubMed ID: 24878374 [TBL] [Abstract][Full Text] [Related]
17. A Fluorescent Peptide Toxin for Selective Visualization of the Voltage-Gated Potassium Channel K Wai DCC; Naseem MU; Mocsár G; Babu Reddiar S; Pan Y; Csoti A; Hajdu P; Nowell C; Nicolazzo JA; Panyi G; Norton RS Bioconjug Chem; 2022 Nov; 33(11):2197-2212. PubMed ID: 36330854 [TBL] [Abstract][Full Text] [Related]
18. Functional role of Kv1.1 and Kv1.3 channels in the neoplastic progression steps of three cancer cell lines, elucidated by scorpion peptides. Aissaoui D; Mlayah-Bellalouna S; Jebali J; Abdelkafi-Koubaa Z; Souid S; Moslah W; Othman H; Luis J; ElAyeb M; Marrakchi N; Essafi-Benkhadir K; Srairi-Abid N Int J Biol Macromol; 2018 May; 111():1146-1155. PubMed ID: 29415410 [TBL] [Abstract][Full Text] [Related]
19. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Felix JP; Bugianesi RM; Schmalhofer WA; Borris R; Goetz MA; Hensens OD; Bao JM; Kayser F; Parsons WH; Rupprecht K; Garcia ML; Kaczorowski GJ; Slaughter RS Biochemistry; 1999 Apr; 38(16):4922-30. PubMed ID: 10213593 [TBL] [Abstract][Full Text] [Related]
20. KCNE4 is an inhibitory subunit to Kv1.1 and Kv1.3 potassium channels. Grunnet M; Rasmussen HB; Hay-Schmidt A; Rosenstierne M; Klaerke DA; Olesen SP; Jespersen T Biophys J; 2003 Sep; 85(3):1525-37. PubMed ID: 12944270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]